These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 34210800)

  • 21. Basic CSF parameters and MRZ reaction help in differentiating MOG antibody-associated autoimmune disease versus multiple sclerosis.
    Vlad B; Reichen I; Neidhart S; Hilty M; Lekaditi D; Heuer C; Eisele A; Ziegler M; Reindl M; Lutterotti A; Regeniter A; Jelcic I
    Front Immunol; 2023; 14():1237149. PubMed ID: 37744325
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapy.
    Harrer A; Tumani H; Niendorf S; Lauda F; Geis C; Weishaupt A; Kleinschnitz C; Rauer S; Kuhle J; Stangel M; Weber F; Uhr M; Linnebank M; Wildemann B; Jarius S; Guger M; Ayzenberg I; Chan A; Zettl U; Wiendl H; Pilz G; Hitzl W; Weber JR; Kraus J
    Mult Scler; 2013 Aug; 19(9):1209-12. PubMed ID: 23093485
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The intrathecal, polyspecific and oligoclonal immune response in multiple sclerosis.
    Reiber H; Ungefehr S; Jacobi C
    Mult Scler; 1998 Jun; 4(3):111-7. PubMed ID: 9762657
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Natalizumab treatment reduces L-selectin (CD62L) in CD4+ T cells.
    Spadaro M; Caldano M; Marnetto F; Lugaresi A; Bertolotto A
    J Neuroinflammation; 2015 Aug; 12():146. PubMed ID: 26259673
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Intrathecal oligoclonal and polyspecific immune response in multiple sclerosis].
    Robinson Agramonte MA; Reiber H; Dorta Contreras AJ; Hernández Díaz E
    Rev Neurol; 2001 Nov 1-15; 33(9):809-11. PubMed ID: 11784982
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antibody producing B lineage cells invade the central nervous system predominantly at the time of and triggered by acute Epstein-Barr virus infection: A hypothesis on the origin of intrathecal immunoglobulin synthesis in multiple sclerosis.
    Otto C; Hofmann J; Ruprecht K
    Med Hypotheses; 2016 Jun; 91():109-113. PubMed ID: 27142157
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intrathecal antibody (IgG) production against human herpesvirus type 6 occurs in about 20% of multiple sclerosis patients and might be linked to a polyspecific B-cell response.
    Derfuss T; Hohlfeld R; Meinl E
    J Neurol; 2005 Aug; 252(8):968-71. PubMed ID: 15772735
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A multicenter, non-interventional study to evaluate the disease activity in Multiple Sclerosis after withdrawal of Natalizumab in Portugal.
    Ladeira F; Braz L; Salgado P; Vaz S; Leitão L; Félix C; Correia AS; Silva AMD; Salgado V; Ferreira F; Vale J; Sá MJ; Capela C
    Clin Neurol Neurosurg; 2019 Sep; 184():105390. PubMed ID: 31306895
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MS and clinically isolated syndromes: shared specificity but diverging clonal patterns of virus-specific IgG antibodies produced in vivo and by CSF B cells in vitro.
    Skorstad G; Vandvik B; Vartdal F; Holmøy T
    Eur J Neurol; 2009 Oct; 16(10):1124-9. PubMed ID: 19469834
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intrathecal polyspecific immune response to neurotropic viruses in multiple sclerosis: a comparative report from Cuban patients.
    Robinson-Agramonte M; Reiber H; Cabrera-Gomez JA; Galvizu R
    Acta Neurol Scand; 2007 May; 115(5):312-8. PubMed ID: 17489941
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacodynamics of natalizumab extended interval dosing in MS.
    Zhovtis Ryerson L; Li X; Goldberg JD; Hoyt T; Christensen A; Metzger RR; Kister I; Foley J
    Neurol Neuroimmunol Neuroinflamm; 2020 Mar; 7(2):. PubMed ID: 32019876
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multiple sclerosis. Electrofocused "bands" of oligoclonal CSF IgG do not carry antibody activity against measles, varicella-zoster or rotaviruses.
    Vartdal F; Vandvik B
    J Neurol Sci; 1982 Apr; 54(1):99-107. PubMed ID: 6281394
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multiple sclerosis: subclasses of intrathecally synthesized IgG and measles and varicella zoster virus IgG antibodies.
    Vartdal F; Vandvik B
    Clin Exp Immunol; 1983 Dec; 54(3):641-7. PubMed ID: 6317243
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pattern II and pattern III MS are entities distinct from pattern I MS: evidence from cerebrospinal fluid analysis.
    Jarius S; König FB; Metz I; Ruprecht K; Paul F; Brück W; Wildemann B
    J Neuroinflammation; 2017 Aug; 14(1):171. PubMed ID: 28851393
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The complex relationship between oligoclonal bands, lymphocytes in the cerebrospinal fluid, and immunoglobulin G antibodies in multiple sclerosis: Indication of serum contribution.
    Beseler C; Vollmer T; Graner M; Yu X
    PLoS One; 2017; 12(10):e0186842. PubMed ID: 29059249
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of cerebrospinal fluid kappa free light chains with the intrathecal polyspecific antiviral immune response in multiple sclerosis.
    Huss A; Mojib-Yezdani F; Bachhuber F; Fangerau T; Lewerenz J; Otto M; Tumani H; Senel M
    Clin Chim Acta; 2019 Nov; 498():148-153. PubMed ID: 31437445
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increased cortical lesion load and intrathecal inflammation is associated with oligoclonal bands in multiple sclerosis patients: a combined CSF and MRI study.
    Farina G; Magliozzi R; Pitteri M; Reynolds R; Rossi S; Gajofatto A; Benedetti MD; Facchiano F; Monaco S; Calabrese M
    J Neuroinflammation; 2017 Feb; 14(1):40. PubMed ID: 28222766
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Matrix Metalloproteinases Panel in Multiple Sclerosis Patients Treated with Natalizumab: A Possible Answer to Natalizumab Non- Responders.
    Balasa R; Bianca C; Septimiu V; Iunius S; Adina H; Sebastian A; Andreea R; Anca M; Smaranda M
    CNS Neurol Disord Drug Targets; 2018; 17(6):464-472. PubMed ID: 29968546
    [TBL] [Abstract][Full Text] [Related]  

  • 39. JCPyV microRNA in plasma inversely correlates with JCPyV seropositivity among long-term natalizumab-treated relapsing-remitting multiple sclerosis patients.
    Basnyat P; Virtanen E; Elovaara I; Hagman S; Auvinen E
    J Neurovirol; 2017 Oct; 23(5):734-741. PubMed ID: 28831768
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cerebrospinal Fluid Biomarkers in Relation to MRZ Reaction Status in Primary Progressive Multiple Sclerosis.
    Robinson T; Abdelhak A; Bose T; Meinl E; Otto M; Zettl UK; Dersch R; Tumani H; Rauer S; Huss A
    Cells; 2020 Nov; 9(12):. PubMed ID: 33255854
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.